Adaptimmune Therapeutics PLC (ADAP) Set to Announce Earnings on Thursday
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) will post its quarterly earnings results on Thursday, November 2nd. Analysts expect Adaptimmune Therapeutics PLC to post earnings of ($0.23) per share for the quarter.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.24). The business had revenue of $3.52 million for the quarter, compared to analysts’ expectations of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. On average, analysts expect Adaptimmune Therapeutics PLC to post $-0.99 EPS for the current fiscal year and $-1.00 EPS for the next fiscal year.
Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at 6.97 on Thursday. The firm has a 50-day moving average of $8.04 and a 200-day moving average of $8.04. The stock’s market cap is $651.83 million. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.29.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.